Adial Pharmaceuticals (ADIL)
(Delayed Data from NSDQ)
$0.97 USD
-0.03 (-2.56%)
Updated Oct 1, 2024 03:59 PM ET
After-Market: $0.96 -0.01 (-1.38%) 7:58 PM ET
4-Sell of 5 4
F Value A Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.97 USD
-0.03 (-2.56%)
Updated Oct 1, 2024 03:59 PM ET
After-Market: $0.96 -0.01 (-1.38%) 7:58 PM ET
4-Sell of 5 4
F Value A Growth A Momentum C VGM
Zacks News
Is Masimo (MASI) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Masimo (MASI) and Adial Pharmaceuticals, Inc. (ADIL) have performed compared to their sector so far this year.
All You Need to Know About Adial Pharmaceuticals, Inc. (ADIL) Rating Upgrade to Buy
by Zacks Equity Research
Adial Pharmaceuticals, Inc. (ADIL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Adial (ADIL) Shares Up 43% in the Past Week: Here's Why
by Zacks Equity Research
Adial (ADIL) shares rise 43% in the past week after the company announced positive regulatory updates on its only pipeline candidate, AD04, for the treatment of alcohol use disorder.
Is Adial Pharmaceuticals (ADIL) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Adial Pharmaceuticals, Inc. (ADIL) and Adverum Biotechnologies (ADVM) have performed compared to their sector so far this year.
Adial Pharmaceuticals, Inc. (ADIL) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
by Zacks Equity Research
Adial Pharmaceuticals, Inc. (ADIL) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Forget Bargain Hunting: Play 5 Stocks With Rising P/E
by Sanghamitra Saha
Bet on these top-ranked stocks with rising P/E to realize outsized gains. Tap Eastside Distilling (EAST), Adial Pharmaceuticals (ADIL), The Buckle (BKE), Ruth's Hospitality Group (RUTH), Insight Enterprises (NSIT).
Here's Why Adial Pharmaceuticals, Inc. (ADIL) Could be Great Choice for a Bottom Fisher
by Zacks Equity Research
Adial Pharmaceuticals, Inc. (ADIL) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Zacks.com featured highlights include Eastside Distilling, Adial Pharmaceuticals, The Buckle, Ruth's Hospitality Group and Insight Enterprises
by Zacks Equity Research
Eastside Distilling, Adial Pharmaceuticals, The Buckle, Ruth's Hospitality Group and Insight Enterprises are part of Zacks Screen of the Week article.
Forget Bargain Hunting: Play 5 Stocks With Rising P/E
by Sanghamitra Saha
Bet on these top-ranked stocks with rising P/E to realize outsized gains. Tap Eastside Distilling (EAST), Adial Pharmaceuticals (ADIL), The Buckle (BKE), Ruth's Hospitality Group (RUTH), Insight Enterprises (NSIT).
Adial Pharmaceuticals, Inc. (ADIL) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
by Zacks Equity Research
Adial Pharmaceuticals, Inc. (ADIL) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
5 Winning Stocks Backed by the Overlooked Rising P/E Strategy
by Sanghamitra Saha
Want to try an out-of-the-box approach? Tap five stocks (GIII, PPC, TAL, ADIL and CHS) with increasing P/E ratios.
Is Adial Pharmaceuticals, Inc. (ADIL) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Adial Pharmaceuticals, Inc. (ADIL) and Albireo Pharma (ALBO) have performed compared to their sector so far this year.